105176-66-7

Usage

Uses

Used in Pharmaceutical Industry:
Bicyclo[2.2.2]octane-1-Methanol, 4-aMinois used as a building block for the synthesis of various pharmaceutical agents and biologically active compounds. Its unique structure and functional groups make it a valuable component in the development of new drugs and pharmaceuticals.
Used in Academic Research:
In academic research, Bicyclo[2.2.2]octane-1-Methanol, 4-aMinoserves as a starting material for the preparation of complex organic molecules. Its versatile structure allows researchers to explore its potential in the synthesis of novel compounds with potential applications in various fields.
Used in Medicinal Chemistry:
Bicyclo[2.2.2]octane-1-Methanol, 4-aMinohas potential applications in the field of medicinal chemistry for the development of new drugs and pharmaceuticals. Its unique structure and functional groups can be utilized to design and synthesize compounds with specific therapeutic properties, contributing to the advancement of drug discovery and development.

Upstream product

• 135908-45-1 ethyl 4-aminobicyclo[2.2.2]octane-1-carboxylate 
• 13595-17-0 4-amino-bicyclo[2.2.2]octane-1-carboxylic acid 
• 949153-20-2 ethyl 4-amino-bicyclo[2.2.2]octane-1-carboxylate hydrochloride 
• 854214-59-8 4-amino-bicyclo[2.2.2]octane-1-carboxylic acid ; hydrochloride 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 1459-96-7 dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate 
• 106004-06-2 dimethyl 1-(2'-chloroethyl)cyclohexane-1,4-dicarboxylate 

Downstream Products

• 1333384-43-2 tert-butyl (4-(hydroxymethyl)bicyclo[2.2.2]octane-1-yl)carbamate 

Relevant academic research and scientific papers

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

BICYCLO DERIVATIVE

A novel bicyclo derivative represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, acts as an effective DPP-IV inhibitor: One example is (2S,4S)-1-[[N-(4-methylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidi